Scholarlink

Purpose <p>The hypertensive phase (HP) following the implantation of a glaucoma drainage device (GDD) is a clinical challenge. We aimed to evaluate the risk factors, clinical features, and correlation of the HP with efficacy in a cohort of glaucoma patients who received a Paul glaucoma implant (PGI).</p> Study design <p>This was a single-center retrospective cohort study (Hospital Clínic of Barcelona).</p> Methods <p>Eighty-three eyes from 71 patients who underwent implantation of a PGI were included, with follow-up extending for up to 2 years. Intraocular pressure (IOP) was measured preoperatively, and at 1 day; 1 week; and 1, 3, 6, 12, and 24 months, postoperatively. Four different success criteria were established: criterion A: IOP &lt;21 mm Hg; criterion B: &lt;18 mm Hg; criterion C: &lt;15 mm Hg; criterion D: &lt;12 mm Hg. The numbers of postoperative IOP-lowering drops, complications, characteristics related to the presence or absence of an HP, and timing of prolene stent removal, among others, were recorded.</p> Results <p>We observed a total of 23 cases (27.7% with an HP). On multivariate analysis we identified younger age (<i>P</i> = .028) and elevated IOP 1 month after surgery (<i>P</i> = .001) as independent risk factors. IOPs were significantly higher (<i>P</i> &lt;.05) in the HP group at 1 week and at 1, 3, and 6 months postoperatively. After 12 months of follow-up, no differences were found between the 2 groups.</p> Conclusion <p>The occurrence of an HP with a PGI does not seem to impact surgical success beyond 12 months postoperatively. However, further research is needed to better understand the underlying mechanisms of HP development and its clinical impact.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Hypertensive phase after a novel small-lumen non-valved drainage device: predictive factors and two-year outcomes

  • 期刊论文

  • 发表日期：

    2025年11月21日

查看全文
  • Francesc Franquesa-Garcia,
  • Sara Labay-Tejado,
  • Néstor Ventura-Abreu,
  • Jordi Izquierdo-Serra,
  • Valeria Opazo-Toro,
  • Elena Milla

摘要

Purpose

The hypertensive phase (HP) following the implantation of a glaucoma drainage device (GDD) is a clinical challenge. We aimed to evaluate the risk factors, clinical features, and correlation of the HP with efficacy in a cohort of glaucoma patients who received a Paul glaucoma implant (PGI).

Study design

This was a single-center retrospective cohort study (Hospital Clínic of Barcelona).

Methods

Eighty-three eyes from 71 patients who underwent implantation of a PGI were included, with follow-up extending for up to 2 years. Intraocular pressure (IOP) was measured preoperatively, and at 1 day; 1 week; and 1, 3, 6, 12, and 24 months, postoperatively. Four different success criteria were established: criterion A: IOP <21 mm Hg; criterion B: <18 mm Hg; criterion C: <15 mm Hg; criterion D: <12 mm Hg. The numbers of postoperative IOP-lowering drops, complications, characteristics related to the presence or absence of an HP, and timing of prolene stent removal, among others, were recorded.

Results

We observed a total of 23 cases (27.7% with an HP). On multivariate analysis we identified younger age (P = .028) and elevated IOP 1 month after surgery (P = .001) as independent risk factors. IOPs were significantly higher (P <.05) in the HP group at 1 week and at 1, 3, and 6 months postoperatively. After 12 months of follow-up, no differences were found between the 2 groups.

Conclusion

The occurrence of an HP with a PGI does not seem to impact surgical success beyond 12 months postoperatively. However, further research is needed to better understand the underlying mechanisms of HP development and its clinical impact.